Skip to Main Content

We have a new app!

Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.

Download the Access App here: iOS and Android. Learn more here!


Content Update


ATTRibute-CM was a phase 3 clinical trial evaluating the impact of acoramidis, a small molecule stabilizer of tranthyretin (TTR), for individuals with TTR amyloidosis cardiomyopathy. Read More

Chapter Summary

This chapter discusses prevalence, pathophysiology, contemporary invasive and noninvasive diagnosis, and emerging management strategies for cardiac amyloidosis, including both wildtype and variant transthyretin disease as well as light-chain disease (see Fuster and Hurst's Central Illustration). Novel therapies can alter the natural history of cardiac amyloidosis and thus the condition should be considered as a differential diagnosis in any individual with heart failure with preserved ejection fraction, increased left ventricular wall thickness beyond 1.2 cm, and other concerning comorbid conditions including but not limited to atrial fibrillation, carpal tunnel syndrome, and autonomic dysfunction. In variant transthyretin amyloidosis, particularly the V142I pathogenic variant affecting 3% to 4% of Black Americans, facilitating genetic cascade testing in first-degree family members, and subsequent earlier recognition of phenotypic disease and treatment with transthyretin stabilizers, may result in slower disease progression and greater mortality benefit. Ongoing clinical trials using transthyretin silencers may dramatically alter the field if they also show morality benefit and less disease progression for both wildtype and/or variant disease. Additionally, if left untreated, light-chain cardiac amyloidosis is a very fatal disease; however, achieving hematologic response in patients with the condition, either with chemotherapy with bortezomib-based regimens or the anti-CD-38 monoclonal antibody daratumumab, can substantially alter prognosis.

eFig 43-01 Chapter 43: Cardiac Amyloidosis


Rudolf Virchow described the reaction of amyloid deposits with iodine and sulfuric acid in 1853. Because this reaction was positive, he assumed that these deposits were starch-like and coined the term amyloid (derived from amylum, the Latin word for “starch”)1 (Fig. 43–1). However, they were later found to be devoid of cellulose by Carl Freidreich and in fact were more albuminoid.2 In ensuing decades after the introduction of Congo red staining, they were found to have apple-green birefringence under polarized light with a beta pleat structure composing the amyloid fibers.

Figure 43–1.

(A) and (B) Cardiac amyloid, note the marked thickening of the right and left ventricular walls. The white deposits of amyloid resulted in the incorrect labeling as "lardaceous degeneration" by Rokitansky in 1842 as "resembling bacon".


Today, amyloidosis reflects a localized or systemic process as a result of at least 30 precursor proteins that destabilize, rearranging into such beta-pleated sheets that make up the fibers that can deposit in various organs. Amyloid deposits are all extracellular and appear hyaline-like and amorphous when stained with hematoxylin and eosin (Fig. 43–2). As mentioned, under polarized light, amyloid deposits exhibit apple-green birefringence with Congo ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.